FDA Drug Approval Process Under Scrutiny: Insights from Biogen and Sarepta's Rapid Approvals

The recent approvals of drugs from Biogen and Sarepta have sparked significant debate regarding the Federal Drug Administration's (FDA) regulatory processes, raising questions about the thoroughness and consistency of drug reviews. A detailed report indicates that these swift approvals may highlight gaps within the FDA's existing frameworks.

Continue reading